Intellia Therapeutics Financial Statements
NASDAQ: NTLAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Intellia Therapeutics revenue and earnings
In fiscal 2025, Intellia Therapeutics generated $67.7 million in revenue, up 16.9% from fiscal 2024, its 2nd consecutive year of revenue growth. Intellia Therapeutics reported a net loss of $412.7 million, compared with a loss of $519.0 million a year earlier. Operating margin was -651.7%.
Diluted earnings per share came in at -$3.81. Over the last 5 fiscal years, NTLA's revenue has grown at a 3.1% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Intellia Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67.67M | 57.88M | 36.27M | 52.12M | 33.05M | 57.99M | 43.10M | 30.43M | 26.12M | 16.48M |
| Revenue growth (YoY) | +16.92% | +59.55% | -30.40% | +57.69% | -43.01% | +34.55% | +41.63% | +16.53% | +58.49% | — |
| Cost of Revenue | — | — | — | — | 0 | 0 | 0 | 0 | — | — |
| Gross Profit | — | — | — | — | 33.05M | 57.99M | 43.10M | 30.43M | — | — |
| Operating Expenses | — | — | — | — | 300.90M | 194.58M | 149.47M | 121.30M | — | — |
| Research & Development | 388.86M | 466.31M | 435.07M | 419.98M | 229.81M | 150.41M | 108.41M | 89.11M | 67.65M | 31.84M |
| Operating Income | -440.99M | -534.26M | -515.29M | -458.16M | -267.85M | -136.58M | -106.37M | -90.87M | -69.56M | -32.16M |
| Other Income (Expense) | 28.30M | 15.24M | 34.10M | -16.02M | -42.00K | 2.35M | 6.83M | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — | -67.54M | -31.63M |
| Income Tax | 0 | — | — | — | — | — | — | — | — | 0 |
| Net Income | -412.69M | -519.02M | -481.19M | -474.19M | -267.89M | -134.23M | -474.19M | -85.34M | -67.54M | -31.63M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -3.81 | -5.25 | -5.42 | -6.16 | -3.78 | -2.40 | -2.11 | -1.98 | -1.88 | -1.42 |
| EPS (Diluted) | -3.81 | -5.25 | -5.42 | -6.16 | -3.78 | -2.40 | -2.11 | -1.98 | -1.88 | -1.42 |
| Shares Outstanding (Basic) | 108.38M | 98.85M | 88.77M | 76.97M | 70.89M | 55.99M | 47.25K | 43.07M | 36.01M | 22.22M |
| Shares Outstanding (Diluted) | 108.38M | 98.85M | 88.77M | 76.97M | 70.89M | 55.99M | 47.25K | 43.07M | 36.01M | 22.22M |
| EBITDA | -431.22M | -523.98M | -506.31M | -450.59M | -260.96M | -130.27M | -100.78M | -86.41M | -66.56M | -31.05M |
| Gross Margin | — | — | — | — | 100.00% | 100.00% | 100.00% | 100.00% | — | — |
| Operating Margin | -651.67% | -923.10% | -1420.51% | -879.04% | -810.37% | -235.51% | -246.78% | -298.58% | -266.32% | -195.15% |
| Net Margin | -609.85% | -896.77% | -1326.51% | -909.78% | -810.49% | -231.46% | -1100.12% | -280.42% | -258.62% | -191.97% |
This table shows 10 annual periods of Intellia Therapeutics's income statement, from FY 2025 back to FY 2016, across 18 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow NTLA's reporting calendar. What is a income statement?